Tofacitinib is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking the action of certain enzymes that are involved in the body's inflammatory response. Tofacitinib is taken orally, usually twice daily. It is available in both tablet and solution form. Tofacitinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the first JAK inhibitor to be approved for the treatment of immune disorders. Since its approval, it has become a popular treatment option for many patients. The market for Tofacitinib is highly competitive, with several companies offering the drug. These include Pfizer, Novartis, AbbVie, and Merck. Each company has its own formulation of the drug, and they compete on price, efficacy, and safety. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
